Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

32 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Nobiletin in Cancer Therapy; Mechanisms and Therapy Perspectives.
Moazamiyanfar R, Rezaei S, AliAshrafzadeh H, Rastegar-Pouyani N, Jafarzadeh E, Mouludi K, Khodamoradi E, Zhaleh M, Taeb S, Najafi M. Moazamiyanfar R, et al. Among authors: rastegar pouyani n. Curr Pharm Des. 2023;29(22):1713-1728. doi: 10.2174/1381612829666230426115424. Curr Pharm Des. 2023. PMID: 37185325 Review.
Modulation of the immune system by melatonin; implications for cancer therapy.
Moslehi M, Moazamiyanfar R, Dakkali MS, Rezaei S, Rastegar-Pouyani N, Jafarzadeh E, Mouludi K, Khodamoradi E, Taeb S, Najafi M. Moslehi M, et al. Int Immunopharmacol. 2022 Jul;108:108890. doi: 10.1016/j.intimp.2022.108890. Epub 2022 May 24. Int Immunopharmacol. 2022. PMID: 35623297 Review.
Apigenin in cancer therapy: Prevention of genomic instability and anticancer mechanisms.
Moslehi M, Rezaei S, Talebzadeh P, Ansari MJ, Jawad MA, Jalil AT, Rastegar-Pouyani N, Jafarzadeh E, Taeb S, Najafi M. Moslehi M, et al. Among authors: rastegar pouyani n. Clin Exp Pharmacol Physiol. 2023 Jan;50(1):3-18. doi: 10.1111/1440-1681.13725. Epub 2022 Oct 13. Clin Exp Pharmacol Physiol. 2023. PMID: 36111951 Review.
Induction of Cancer Cell Death by Apigenin: A Review on Different Cell Death Pathways.
Amini P, Moazamiyanfar R, Dakkali MS, Jafarzadeh E, Ganjizadeh M, Rastegar-Pouyani N, Moloudi K, Khodamoradi E, Taeb S, Najafi M. Amini P, et al. Among authors: rastegar pouyani n. Mini Rev Med Chem. 2023;23(14):1461-1478. doi: 10.2174/1389557523666230119110744. Mini Rev Med Chem. 2023. PMID: 36658710 Review.
Resveratrol as an antitumor agent for glioblastoma multiforme: Targeting resistance and promoting apoptotic cell deaths.
Karkon-Shayan S, Aliashrafzadeh H, Dianat-Moghadam H, Rastegar-Pouyani N, Majidi M, Zarei M, Moradi-Vastegani S, Bahramvand Y, Babaniamansour S, Jafarzadeh E. Karkon-Shayan S, et al. Among authors: rastegar pouyani n. Acta Histochem. 2023 Aug;125(6):152058. doi: 10.1016/j.acthis.2023.152058. Epub 2023 Jun 17. Acta Histochem. 2023. PMID: 37336070 Review.
The Impact of Cancer-Associated Fibroblasts on Drug Resistance, Stemness, and Epithelial-Mesenchymal Transition in Bladder Cancer: A Comparison between Recurrent and Non-Recurrent Patient-Derived CAFs.
Rastegar-Pouyani N, Montazeri V, Marandi N, Aliebrahimi S, Andalib M, Jafarzadeh E, Montazeri H, Ostad SN. Rastegar-Pouyani N, et al. Cancer Invest. 2023 Sep;41(7):656-671. doi: 10.1080/07357907.2023.2237576. Epub 2023 Jul 23. Cancer Invest. 2023. PMID: 37462514
32 results